Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

Brolucizumab

Aliases
Beovu, Brolucizumab 6mg, Brolucizumab 6 mg, ESBA1008 (2 other aliases)
Name
BEOVU
INN Name
brolucizumab
FDA Approved
Yes

15 clinical trials

1 organization

10 indications

1 document

Indication
Diabetic Macular Edema
Indication
Macular Degeneration
Indication
Diabetic Retinopathy
Indication
Age-Related Macular Degeneration
Indication
Macular Polypoidal Choroidal Vasculopathy (PCV)
Indication
Retinal Vein Occlusion
Indication
Age-related macular degeneration
Indication
Central Retinal Vein Occlusion
Indication
Age-related Macular Degeneration
Indication
Neovascular Age-related Macular Degeneration
Clinical trial
A Two-Year, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Diabetic Macular Edema
Status: Completed, Estimated PCD: 2020-06-29
Clinical trial
A 64-week, Two-arm, Randomized, Double-masked, Multicenter, Phase IIIb Study Assessing the Efficacy and Safety of Brolucizumab 6 mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen in Patients With Neovascular Agerelated Macular Degeneration (TALON)
Status: Completed, Estimated PCD: 2022-09-09
Clinical trial
A 96-week, Two-arm, Randomized, Single-masked, Multi-center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab 6 mg Compared to Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy
Status: Active (not recruiting), Estimated PCD: 2023-10-30
Clinical trial
A Twelve-Month, Randomized, Double-Masked, Multicenter, Phase III, Two-Arm Study Comparing the Efficacy and Safety of Brolucizumab 6 mg Versus Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration
Status: Completed, Estimated PCD: 2024-02-28
Clinical trial
One Year, Single Arm, Open Label, Multicenter, Phase IV Study Using Multimodal Imaging to Guide Disease Activity Assessment Through Innovative Early Predictive Anatomical Biomarkers of Fluid Resolution in wAMD Patients Treated With Brolucizumab- IMAGINE Study
Status: Completed, Estimated PCD: 2023-10-04
Clinical trial
A 52-week, Two Arm, Randomized, Open-label, Multicenter Study Assessing the Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens for Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration
Status: Completed, Estimated PCD: 2024-01-31
Clinical trial
A 60-week, Phase IIIb, Randomized, Multi-center Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PROUD Study)
Status: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
A Multicenter, Randomized, Double-masked Phase 3a Study to Assess Safety and Efficacy of Brolucizumab 6 mg q4 Weeks Compared to Aflibercept 2 mg q4 Weeks in Patients With Neovascular Age-related Macular Degeneration (nAMD) With Persistent Retinal Fluid (MERLIN)
Status: Terminated, Estimated PCD: 2020-12-21
Clinical trial
An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion
Status: Terminated, Estimated PCD: 2021-07-26
Clinical trial
An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion
Status: Terminated, Estimated PCD: 2021-07-26
Clinical trial
A One-Year, Randomized, Double-Masked, Multicenter, Phase III, Two-Arm Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Chinese Patients With Visual Impairment Due to Diabetic Macular Edema
Status: Completed, Estimated PCD: 2023-01-31
Clinical trial
A Two-year, Three-arm, Randomized, Double-masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Diabetic Macular Edema
Status: Completed, Estimated PCD: 2020-11-11
Clinical trial
Study Comparing Early Extension of Aflibercept and Brolucizumab in Wet AMD (SPARROW)
Status: , Estimated PCD: 2027-06-01
Clinical trial
Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for Neovascular Age-related Macular Degeneration (nAMD) in Portugal
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With a Novel Treat and Extend Protocol - a Randomized Controlled Prospective Study
Status: Completed, Estimated PCD: 2023-07-25
Document
DailyMed Label: BEOVU
Organization
Novartis Pharmaceuticals Corporation